South Korea · Delayed Price · Currency is KRW Seoul Pharma Statistics
Total Valuation
Seoul Pharma has a market cap or net worth of KRW 24.31 billion. The enterprise value is 23.41 billion.
| Market Cap | 24.31B |
| Enterprise Value | 23.41B |
Important Dates
| Earnings Date | n/a |
| Ex-Dividend Date | n/a |
Share Statistics
Seoul Pharma has 11.66 million shares outstanding.
| Current Share Class | 11.66M |
| Shares Outstanding | 11.66M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 0.07% |
| Owned by Institutions (%) | n/a |
| Float | 4.72M |
Valuation Ratios
The trailing PE ratio is 33.49.
| PE Ratio | 33.49 |
| Forward PE | n/a |
| PS Ratio | 0.47 |
| PB Ratio | 0.59 |
| P/TBV Ratio | 0.61 |
| P/FCF Ratio | 2.42 |
| P/OCF Ratio | 2.22 |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 17.83, with an EV/FCF ratio of 2.33.
| EV / Earnings | 32.24 |
| EV / Sales | 0.46 |
| EV / EBITDA | 17.83 |
| EV / EBIT | n/a |
| EV / FCF | 2.33 |
Financial Position
The company has a current ratio of 2.38, with a Debt / Equity ratio of 0.42.
| Current Ratio | 2.38 |
| Quick Ratio | 1.59 |
| Debt / Equity | 0.42 |
| Debt / EBITDA | 13.12 |
| Debt / FCF | 1.72 |
| Interest Coverage | -2.34 |
Financial Efficiency
Return on equity (ROE) is 1.80% and return on invested capital (ROIC) is -3.05%.
| Return on Equity (ROE) | 1.80% |
| Return on Assets (ROA) | -1.19% |
| Return on Invested Capital (ROIC) | -3.05% |
| Return on Capital Employed (ROCE) | -2.38% |
| Weighted Average Cost of Capital (WACC) | 4.95% |
| Revenue Per Employee | 298.41M |
| Profits Per Employee | 4.22M |
| Employee Count | 172 |
| Asset Turnover | 0.72 |
| Inventory Turnover | 1.73 |
Taxes
| Income Tax | -49.60M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -39.12% in the last 52 weeks. The beta is 0.42, so Seoul Pharma's price volatility has been lower than the market average.
| Beta (5Y) | 0.42 |
| 52-Week Price Change | -39.12% |
| 50-Day Moving Average | 2,590.70 |
| 200-Day Moving Average | 2,901.98 |
| Relative Strength Index (RSI) | 32.51 |
| Average Volume (20 Days) | 9,988 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Seoul Pharma had revenue of KRW 51.33 billion and earned 725.89 million in profits. Earnings per share was 62.26.
| Revenue | 51.33B |
| Gross Profit | 30.89B |
| Operating Income | -1.35B |
| Pretax Income | 676.29M |
| Net Income | 725.89M |
| EBITDA | 1.31B |
| EBIT | -1.35B |
| Earnings Per Share (EPS) | 62.26 |
Balance Sheet
The company has 18.13 billion in cash and 17.22 billion in debt, with a net cash position of 903.78 million or 77.52 per share.
| Cash & Cash Equivalents | 18.13B |
| Total Debt | 17.22B |
| Net Cash | 903.78M |
| Net Cash Per Share | 77.52 |
| Equity (Book Value) | 40.86B |
| Book Value Per Share | 3,504.32 |
| Working Capital | 19.48B |
Cash Flow
In the last 12 months, operating cash flow was 10.95 billion and capital expenditures -910.37 million, giving a free cash flow of 10.04 billion.
| Operating Cash Flow | 10.95B |
| Capital Expenditures | -910.37M |
| Depreciation & Amortization | 2.66B |
| Net Borrowing | 1.37B |
| Free Cash Flow | 10.04B |
| FCF Per Share | 861.30 |
Margins
Gross margin is 60.18%, with operating and profit margins of -2.63% and 1.41%.
| Gross Margin | 60.18% |
| Operating Margin | -2.63% |
| Pretax Margin | 1.32% |
| Profit Margin | 1.41% |
| EBITDA Margin | 2.56% |
| EBIT Margin | -2.63% |
| FCF Margin | 19.57% |
Dividends & Yields
Seoul Pharma does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | n/a |
| Shareholder Yield | n/a |
| Earnings Yield | 2.99% |
| FCF Yield | 41.31% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | |
| Lynch Upside | |
| Graham Number | |
| Graham Upside |
Stock Splits
The last stock split was on April 12, 2004. It was a forward split with a ratio of 2.
| Last Split Date | Apr 12, 2004 |
| Split Type | Forward |
| Split Ratio | 2 |
Scores
Seoul Pharma has an Altman Z-Score of 1.84 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.84 |
| Piotroski F-Score | 4 |